CORT Relative Valuation
CORT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CORT is overvalued; if below, it's undervalued.
Historical Valuation
Corcept Therapeutics Inc (CORT) is now in the Overvalued zone, suggesting that its current forward PE ratio of 109.38 is considered Overvalued compared with the five-year average of 32.74. The fair price of Corcept Therapeutics Inc (CORT) is between 27.51 to 47.81 according to relative valuation methord. Compared to the current price of 84.66 USD , Corcept Therapeutics Inc is Overvalued By 77.07%.
Relative Value
Fair Zone
27.51-47.81
Current Price：84.66
77.07%
Overvalued
109.38
PE
1Y
3Y
5Y
Trailing
Forward
30.56
EV/EBITDA
Corcept Therapeutics Inc. (CORT) has a current EV/EBITDA of 30.56. The 5-year average EV/EBITDA is 18.84. The thresholds are as follows: Strongly Undervalued below 6.22, Undervalued between 6.22 and 12.53, Fairly Valued between 25.16 and 12.53, Overvalued between 25.16 and 31.47, and Strongly Overvalued above 31.47. The current Forward EV/EBITDA of 30.56 falls within the Overvalued range.
65.14
EV/EBIT
Corcept Therapeutics Inc. (CORT) has a current EV/EBIT of 65.14. The 5-year average EV/EBIT is 21.55. The thresholds are as follows: Strongly Undervalued below -1.28, Undervalued between -1.28 and 10.14, Fairly Valued between 32.97 and 10.14, Overvalued between 32.97 and 44.38, and Strongly Overvalued above 44.38. The current Forward EV/EBIT of 65.14 falls within the Strongly Overvalued range.
8.52
PS
Corcept Therapeutics Inc. (CORT) has a current PS of 8.52. The 5-year average PS is 6.12. The thresholds are as follows: Strongly Undervalued below 3.38, Undervalued between 3.38 and 4.75, Fairly Valued between 7.49 and 4.75, Overvalued between 7.49 and 8.87, and Strongly Overvalued above 8.87. The current Forward PS of 8.52 falls within the Overvalued range.
62.60
P/OCF
Corcept Therapeutics Inc. (CORT) has a current P/OCF of 62.60. The 5-year average P/OCF is 20.78. The thresholds are as follows: Strongly Undervalued below 0.96, Undervalued between 0.96 and 10.87, Fairly Valued between 30.68 and 10.87, Overvalued between 30.68 and 40.59, and Strongly Overvalued above 40.59. The current Forward P/OCF of 62.60 falls within the Strongly Overvalued range.
62.60
P/FCF
Corcept Therapeutics Inc. (CORT) has a current P/FCF of 62.60. The 5-year average P/FCF is 21.96. The thresholds are as follows: Strongly Undervalued below 1.46, Undervalued between 1.46 and 11.71, Fairly Valued between 32.21 and 11.71, Overvalued between 32.21 and 42.45, and Strongly Overvalued above 42.45. The current Forward P/FCF of 62.60 falls within the Strongly Overvalued range.
Corcept Therapeutics Inc (CORT) has a current Price-to-Book (P/B) ratio of 14.08. Compared to its 3-year average P/B ratio of 7.57 , the current P/B ratio is approximately 86.15% higher. Relative to its 5-year average P/B ratio of 6.74, the current P/B ratio is about 108.90% higher. Corcept Therapeutics Inc (CORT) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 3.85%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 4.72% , the current FCF yield is about -100.00% lower.
14.08
P/B
Median3y
7.57
Median5y
6.74
1.85
FCF Yield
Median3y
3.85
Median5y
4.72
Competitors Valuation Multiple
The average P/S ratio for CORT's competitors is , providing a benchmark for relative valuation. Corcept Therapeutics Inc Corp (CORT) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 13.75%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CORT increased by 68.01% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 44.53 to 96.93.
The secondary factor is the Revenue Growth, contributed 13.75%to the performance.
Overall, the performance of CORT in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Corcept Therapeutics Inc (CORT) currently overvalued or undervalued?
What is Corcept Therapeutics Inc (CORT) fair value?
How does CORT's valuation metrics compare to the industry average?
What is the current P/B ratio for Corcept Therapeutics Inc (CORT) as of Dec 05 2025?
What is the current FCF Yield for Corcept Therapeutics Inc (CORT) as of Dec 05 2025?
What is the current Forward P/E ratio for Corcept Therapeutics Inc (CORT) as of Dec 05 2025?